戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 psoriasis, antinuclear antibodies [ANA], and rheumatoid factor).
2 ucleoproteins (snRNPs), dsDNA, and self IgG (rheumatoid factor).
3 -cyclic citrullinated peptide (anti-CCP) and rheumatoid factor.
4 ng peak levels of antihistone, anti-DNA, and rheumatoid factor.
5 n of disease, level of formal education, and rheumatoid factor.
6  of symptom onset) who were seropositive for rheumatoid factor.
7 ow-affinity, polyreactive human (h)IgM/kappa rheumatoid factor.
8      Both DQ8.CD8(-/-) and DQ8 mice produced rheumatoid factor.
9 t nodules in the absence of detectable serum rheumatoid factor.
10 y stronger in patients who were positive for rheumatoid factor.
11 ted to patients whose sera were negative for rheumatoid factor.
12 ic, nuclear, and platelet autoantibodies and rheumatoid factor.
13  anti-chromatin, anti-dsDNA, anti-ssDNA, and rheumatoid factor.
14 23- B cell secreting immunoglobulin M, kappa rheumatoid factor.
15 mentation rate, C-reactive protein level, or rheumatoid factor.
16 VH gene that partially encodes an anti-IgG2a rheumatoid factor.
17 reased levels of endogenous anti-DNA Abs and rheumatoid factor.
18 red for the development of antichromatin and rheumatoid factor.
19 hyroperoxidase antibody, and 37 positive for rheumatoid factor.
20 inatus correlated with the presence of ACPAs/rheumatoid factor.
21 nts, anti-citrullinated protein antibody and rheumatoid factor.
22 trullinated peptide (anti-CCP) antibody, and rheumatoid factor.
23 evels of anti-dsDNA, anti-chromatin, and IgM rheumatoid factors.
24 ing to the pathogenic potential of 6-19 IgG3 rheumatoid factors.
25 elevated ESR (87 mm/hr), CRP (156 mg/L), and rheumatoid factor (184 IU/mL).
26 s), though none had systemic symptoms: 18.8% rheumatoid factor; 6.25% SS-A/SS-B; 31.3% early Sjogren
27       Anti-CCP2 had greater specificity than rheumatoid factor (96% vs. 86%), with similar sensitivit
28 ma cells producing an IgG3 cryoglobulin with rheumatoid factor activity against IgG2a of allotype a p
29  profile, level of alanine aminotransferase, rheumatoid factor activity, C4 fraction of complement, a
30 -69 encoded antibodies that have anti-IgG or rheumatoid factor activity.
31 te in women and more frequent positivity for rheumatoid factor among both men and women.
32 t circulating autoantibodies, including both rheumatoid factor and anti-citrullinated protein antibod
33 he ability of baseline serum measurements of rheumatoid factor and anti-cyclic citrullinated peptide
34                  Although, reduced titers of rheumatoid factor and anti-cyclic citrullinated peptide
35 r nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide.
36 x studies examined outcome predictions using rheumatoid factor and antikeratin/anticyclic citrullinat
37 variate analysis were AKIN stage 3, positive rheumatoid factor and biclonal gammopathy at diagnosis.
38 mmation, and autoantibodies (particularly to rheumatoid factor and citrullinated peptide).
39                                              Rheumatoid factor and complement C4 levels were normal i
40 ve B cells producing antinuclear antibody or rheumatoid factor and exhibit the skewed Ig V gene reper
41                                              Rheumatoid factor and SE were also predictors to a lesse
42 e, disease duration, and baseline values for rheumatoid factor and the tender and swollen joint count
43 ce gavaged with E. lenta produce preclinical rheumatoid factor and, when induced for arthritis, devel
44 imited range of motion (1 point), absence of rheumatoid factor and/or anti-citrullinated protein anti
45 aracteristics of IgG binding by gE-gI and by rheumatoid factors and bacterial Fc receptors such as St
46 high-sensitivity C-reactive protein (hsCRP), rheumatoid factor, and anti-citrullinated protein antibo
47 a combination of the CSQ, joint examination, rheumatoid factor, and anti-cyclic citrullinated peptide
48 ogic studies for antinuclear antibody (ANA), rheumatoid factor, and antibodies to extractable nuclear
49          A combination of age, sex, smoking, rheumatoid factor, and anticyclic citrullinated peptide
50                                   Serum IgE, rheumatoid factor, and antinuclear antibodies and skin s
51          High mean platelet volume, positive rheumatoid factor, and antinuclear antibodies were all s
52 edimentation rate, C-reactive protein level, rheumatoid factor, and antinuclear antibody levels were
53 on rate, hemoglobin, white count, platelets, rheumatoid factor, and antinuclear factor.
54 une features such as hypergammaglobulinemia, rheumatoid factor, and circulating immune complexes are
55 d for optimal production of IgG autoAbs, IgM rheumatoid factor, and other clinical parameters of dise
56 es to citrullinated protein antigens (ACPA), rheumatoid factor, and symptoms, such as inflammatory jo
57 sociated with serum anti-SSA/SSB positivity, rheumatoid factor, and the ocular component of SS, but n
58 with childhood-onset RA, which is defined as rheumatoid factor- and/or anti-citrullinated protein ant
59  including anti-DNA, anti-Smith antigen, and rheumatoid factor; and glomerulonephritis.
60                          No association with rheumatoid factor, anti-cyclic citrullinated peptide, or
61            YYAA mice, like SKG mice, develop rheumatoid factor antibodies, but fail to develop autoim
62 otein, erythrocyte sedimentation rate (ESR), rheumatoid factor, anticitrullinated protein antibodies
63 idence of interaction between the effects of rheumatoid factor, antinuclear antibodies, positive skin
64                          C-reactive protein, rheumatoid factor, antinuclear antibody, cytoplasmic ant
65  looked for a broad range of autoantibodies (rheumatoid factor, antinuclear antibody, smooth muscle a
66                             The frequency of rheumatoid factor at 3 years postinfection was 29.5% and
67 us nodules or finger clubbing, low titers of rheumatoid factor at onset of lung disease, lymphocytosi
68 mphoid malignancy in the formation of public rheumatoid factor autoantibodies responsible for mixed c
69 more severe lupus, as judged by anti-DNA and rheumatoid factor autoantibodies, total serum Ig isotype
70 D88, had markedly reduced chromatin, Sm, and rheumatoid factor autoantibody titers.
71 pendent autoreactive EF response elicited in rheumatoid-factor B cells by DNA-containing immune compl
72 n non-B cells, we transferred anti-self-IgG (rheumatoid factor) B cells and their physiologic target
73 i-IgG2a rheumatoid factor, but not 46-42 IgA rheumatoid factor bearing the same IgA allotype, develop
74 ents have clonal expansions of hypermutated, rheumatoid factor-bearing marginal zone-like IgM(+)CD27(
75 iated with SSc-ILD were anti-CCP antibody or rheumatoid factor (beta coefficient, 2.652 [95% CI 1.472
76 rence from other serum proteins, prealbumin, rheumatoid factor, bilirubin, estrogen, or C-reactive pr
77 tive binding to ssDNA, dsDNA, and IgG (i.e., rheumatoid factor), but not to histones or Sm.
78 with hybridoma secreting 6-19 IgA anti-IgG2a rheumatoid factor, but not 46-42 IgA rheumatoid factor b
79 ndent Ags, including 23 anti-HIV mAbs and 51 rheumatoid factors, but differed from that of 43 Abs to
80                        Mice with FIA possess rheumatoid factor, circulating immune complexes, and ant
81 tions such as the presence of high levels of rheumatoid factors, circulating immune complexes, anti-D
82 o arthritis-related self proteins, including rheumatoid factor, citrullinated peptide, and type II co
83 nti-cyclic citrullinated peptide antibodies, rheumatoid factor, complement levels, and cytokine level
84 rent, and the VH and V kappas encoding these rheumatoid factors contained a high frequency of somatic
85 o patients randomized to receive MTX who had rheumatoid factor data.
86              Monoclonal 6-19 IgG3 anti-IgG2a rheumatoid factor derived from lupus-prone MRL-Fas(lpr)
87 phenotype studies, anti-nuclear antibody and rheumatoid factor determinations, marrow cytogenetics, a
88 l IgG, IgG anti-chromatin, anti-DNA, and IgM rheumatoid factor directed against IgG1 and against IgG2
89 stations in terms of increased production of rheumatoid factors due to TLR ligation on B cells.
90 rted cells, we show that these predominantly rheumatoid factor-encoding V(H)1-69/J(H)4 and V(kappa)3-
91  of severe human RA, including production of rheumatoid factor, enhanced T cell production, and monoc
92 iopathic arthritis (positive or negative for rheumatoid factor), extended oligoarticular juvenile idi
93                          The presence of IgG rheumatoid factor (IgG-RF) preceded the development of a
94                          The presence of IgM rheumatoid factor (IgM-RF), IgG-RF, IgA-RF, and IgG anti
95 o histones (H1-H5) and chromatin and for IgM rheumatoid factors (IgM-RFs).
96                            Low levels of RF (rheumatoid factor), IL-12, and IL-17 were sensitive and
97                                    Small IgG rheumatoid factor immune complexes may provide the trigg
98 ied the presence of these autoantibodies and rheumatoid factor in blood donors who later developed rh
99 electively binds IgG molecules, an important rheumatoid factor in RA.
100                It is characteristic that the rheumatoid factor in serum is absent.
101 y (accumulation of anti-dsDNA antibodies and rheumatoid factor in serum, deposits of IgG and IgM in k
102 tions support a model for the origin of some rheumatoid factors, in which they represent anti-idiotyp
103 gion of mouse IgA and suggests that 6-19 IgA rheumatoid factor-induced GN could serve as an experimen
104                                          The rheumatoid factor is characteristically absent in the se
105 citrullinated peptide antibodies and/or >/=2 rheumatoid factor isotypes (a profile that is 96% specif
106 ambda(s) 29.5), leukocytosis (lambda(s) 25), rheumatoid factor (lambda(s) 11.0), anemia (lambda(s) 1.
107 lammation with local production of ACPAs and rheumatoid factors, leading to development of the 'mucos
108 otein level, erythrocyte sedimentation rate, rheumatoid factor level, tender joint count in 68 joints
109                                          IgG rheumatoid factor levels were significantly lower in the
110 rs with sequelae showed significantly higher rheumatoid factor levels.
111 ctive B cells in BALB/c AM14 transgenic (Tg) rheumatoid factor mice are not subject to central or per
112                               The monoclonal rheumatoid factors (mRF) that bear the WA cross-idiotype
113 ing hyper IgM (n = 9), hyper IgG (n = 8), or rheumatoid factor (n = 55) did not cross-react with the
114 rheumatoid factor positive and 42 (40%) were rheumatoid factor negative.
115                                        Seven rheumatoid factor-negative JRA patients with polyarticul
116 n southern Europe (1360 [56.7%] of 2400) and rheumatoid factor-negative polyarthritis was more freque
117      In 358 children with oligoarthritis and rheumatoid factor-negative polyarthritis, erythrocyte se
118 ligoarthritis, rheumatoid factor-positive or rheumatoid factor-negative polyarthritis, or systemic JI
119  of juvenile idiopathic arthritis (JIA), IgM rheumatoid factor-negative polyarticular JIA and oligoar
120 the most common subtypes (oligoarticular and rheumatoid factor-negative polyarticular JIA), and 13,05
121  with persistent oligoarticular JIA, 45 with rheumatoid factor-negative polyarticular JIA, and 20 wit
122 g); the donor was the patient's HLA-matched, rheumatoid factor-negative sister.
123 ssion analysis determined that psoriasis and rheumatoid factor negativity were the most important fea
124 otein level, erythrocyte sedimentation rate, rheumatoid factor, nodular disease, modified Health Asse
125 t the Health Assessment Questionnaire score, rheumatoid factor, nodules, and swollen joint counts wer
126             Blood chemistry tests revealed a rheumatoid factor of 8.5 IU/mL (normal range, 0-13.9 IU/
127 marker for serodiagnosis of acute infection, rheumatoid factor often causes false-positive reactions.
128 urface of T cells, except in the presence of rheumatoid factor or activated monocytes.
129 rheumatoid arthritis (RA) include those with rheumatoid factor or anti-citrullinated protein antibody
130 CFA was also associated with the presence of rheumatoid factor or antinuclear antibodies, but not wit
131 /lpr mice; however, they did not develop IgG rheumatoid factors or anti-dsDNA, and lacked histologic
132 duction of antibodies to autoantigens (e.g., rheumatoid factor) or exogenous antigens, or it may repr
133 re disease progression, including a positive rheumatoid factor, or anti-cyclic citrullinated peptide
134  IgG deposition, levels of anti-dsDNA Ab and rheumatoid factor, or spleen weights between the two gro
135 ti-citrullinated protein antibodies (ACPAs), rheumatoid factors, or other autoantibodies.
136 Nevertheless, B cells representative of this rheumatoid factor population proliferate vigorously in r
137               Sixty-four (60%) RA cases were rheumatoid factor positive and 42 (40%) were rheumatoid
138             Children, especially girls, with rheumatoid factor positive polyarticular juvenile idiopa
139 -reactive protein level 42 mg/liter, and 65% rheumatoid factor positive).
140   Sixty percent of the patients with RA were rheumatoid factor positive.
141                            All patients were rheumatoid factor positive.
142 69% of whom were female and 66% of whom were rheumatoid factor positive.
143  time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifyin
144 E) alleles were significantly more common in rheumatoid factor-positive (RF+) patients fulfilling the
145 ticular course JIA (extended oligoarthritis, rheumatoid factor-positive or rheumatoid factor-negative
146 iduals, Toxoplasma IgG-negative individuals, rheumatoid factor-positive persons, and persons determin
147 onset) and (2) JIA, except for the systemic, rheumatoid factor-positive polyarthritis, and enthesitis
148 of peripheral blood CD34+,CD45+ HPCs from 63 rheumatoid factor-positive RA patients and 48 controls m
149 n and 1.7% for men, and the lifetime risk of rheumatoid factor-positive RA was 2.4% for women and 1.1
150          Adolescent girls with polyarticular rheumatoid factor-positive subtype appear to be most vul
151 other self-report items, was associated with rheumatoid factor positivity (P = 0.047) and higher dise
152 proved significance when modeling DRB1*04 or rheumatoid factor positivity as covariates.
153                            It was shown that rheumatoid factor positivity does not exclude a diagnosi
154 positive predictive value (PPV) (80.0%), and rheumatoid factor positivity the lowest (44.6%).
155 adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammatory markers (
156 te models, the mean ESR, mean grip strength, rheumatoid factor positivity, and tender joint count wer
157 as no significant association with male sex, rheumatoid factor positivity, or erosive disease.
158 ge, sex, body mass index (BMI), smoking, and rheumatoid factor positivity.
159 er adjusting for age, sex, BMI, smoking, and rheumatoid factor positivity.
160 rmalities including antinuclear antibody and rheumatoid factor positivity.
161 ful in establishing the diagnosis of RA, but rheumatoid factor potentially provides the most useful p
162                We have previously shown that rheumatoid factors produced by Fas-deficient autoimmune-
163 that iNKT cells suppress IgG anti-DNA Ab and rheumatoid factor production and reduce IL-10-secreting
164 ain whether the combination of anti-CCP2 and rheumatoid factor provides additional benefit over anti-
165 indings of others that while the spontaneous rheumatoid factor response of lpr/lpr mice was oligoclon
166 ion pathways at early and late stages of the rheumatoid factor response.
167             B6-derived B cells produced more rheumatoid factor (RF) against their own IgG2b(b), while
168                                              Rheumatoid factor (RF) and anti-CCP were measured in ser
169                                              Rheumatoid factor (RF) and anti-citrullinated protein an
170                                              Rheumatoid factor (RF) and anti-cyclic citrullinated pep
171                                              Rheumatoid factor (RF) and autoantibodies against cyclic
172          Blood was obtained and analyzed for rheumatoid factor (RF) and CRP concentration.
173       Cigarette smoking is known to increase rheumatoid factor (RF) and nodule formation in patients
174                                        Serum rheumatoid factor (RF) and other heterophilic antibodies
175 linical surrogates to substitute for missing rheumatoid factor (RF) and radiologic erosion data was a
176 igins, we traced the evolution of pathogenic rheumatoid factor (RF) autoantibodies in four HCV-cryova
177 prone MRL-lpr/lpr (MRL-lpr) background, AM14 rheumatoid factor (RF) B cells are activated, differenti
178                                              Rheumatoid factor (RF) B cells function as highly effici
179                                         AM14 rheumatoid factor (RF) B cells in the MRL/lpr mice are a
180                     High-affinity pathologic rheumatoid factor (RF) B cells occur in autoimmune disea
181                                              Rheumatoid factor (RF) B cells proliferate during second
182   The proliferative response of autoreactive rheumatoid factor (RF) B cells to mammalian chromatin-co
183 ortant insights on RA and on the function of rheumatoid factor (RF) become apparent.
184 an diseases, autoreactive B cells expressing rheumatoid factor (RF) binding activity are prominent.
185 -cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) has been established.
186                    In this study, we show in rheumatoid factor (RF) Ig-transgenic autoimmune-prone mi
187 .6 years prior to diagnosis) were tested for rheumatoid factor (RF) isotypes, anti-cyclic citrullinat
188 ept significantly reduced immunoglobulin and rheumatoid factor (RF) levels, but not anti-citrullinate
189    Here, using AM14 site-directed transgenic rheumatoid factor (RF) mice, we report that B cells can
190 k was higher among patients with RA who were rheumatoid factor (RF) positive (HR 2.59, 95% CI 1.95-3.
191 l as for the subgroups who were and were not rheumatoid factor (RF) positive at baseline.
192 s with early inflammatory arthritis who were rheumatoid factor (RF) positive, but were predictive in
193                     Sixty-three percent were rheumatoid factor (RF) positive.
194 e swollen joints (8 versus 7), more frequent rheumatoid factor (RF) positivity (93% versus 84%), high
195  population studies have suggested that both rheumatoid factor (RF) production and rheumatoid arthrit
196                                              Rheumatoid factor (RF) production in rheumatoid arthriti
197                                              Rheumatoid factor (RF) production was found to be associ
198                                     Although rheumatoid factor (RF) seropositivity is a risk factor f
199 study was to define the structural basis for rheumatoid factor (RF) specificity and for the expressio
200       In separate analyses, we corrected for rheumatoid factor (RF) status and/or the presence of the
201                                          The rheumatoid factor (RF) status, C-reactive protein levels
202                               Urinalysis and rheumatoid factor (RF) tests were conducted to evaluate
203 viral titers of WB and Pl, percentage of CP, rheumatoid factor (RF) titer, and serum alanine transami
204 osoma parasites, heterophile antibodies, and rheumatoid factor (RF) titers.
205       We have analyzed B cell tolerance in a rheumatoid factor (RF) transgenic mouse model.
206   Patients with RA who were seropositive for rheumatoid factor (RF) were more likely to have moderate
207                             Baseline age and rheumatoid factor (RF) were significantly different betw
208 eline specimens, we measured serum anti-CCP, rheumatoid factor (RF), and antinuclear antibody in a de
209 ous combinations of ICD code 714, a positive rheumatoid factor (RF), and prescription for a disease-m
210  to cyclic citrullinated peptide (anti-CCP), rheumatoid factor (RF), and the 620W PTPN22 allele.
211                    Autoantibodies, including rheumatoid factor (RF), are an important characteristic
212                                              Rheumatoid factor (RF)-expressing B lymphocytes in norma
213  persistent oligoarticular and polyarticular rheumatoid factor (RF)-negative juvenile idiopathic arth
214                                              Rheumatoid factor (RF)-negative patients with exposure t
215 an biomarkers for the classification of both rheumatoid factor (RF)-positive and negative RA patients
216 he onset of rheumatoid arthritis (RA) in 182 rheumatoid factor (RF)-positive European American patien
217 ), particularly in those with polyarticular, rheumatoid factor (RF)-positive JRA.
218                Patients ages 2-18 years with rheumatoid factor (RF)-positive or RF-negative polyarthr
219 ll-cause and CVD mortality were increased in rheumatoid factor (RF)-positive patients and in this sub
220  when restricted to more seriously affected (rheumatoid factor (RF)-positive) patients.
221 the severity of rheumatoid arthritis than is rheumatoid factor (RF).
222 IgG) make a class of autoantibodies known as rheumatoid factor (RF).
223 c citrullinated peptide (CCP) antibodies and rheumatoid factor (RF).
224 zyme-linked immunosorbent assay [ELISA]) and rheumatoid factor (RF; by nephelometry or ELISA for IgA,
225 ism, and approximately 16% were positive for rheumatoid factor (RF; including isotypes) and/or anti-c
226                                              Rheumatoid factors (RF) and the disease-specific anti-ci
227                                              Rheumatoid factors (RF) associated with arthritic joint
228                                              Rheumatoid factors (RF) recognize conformational determi
229              Half of 30 human polyclonal IgM rheumatoid factors (RF) showed positive ELISA reactions
230 tibodies including IgA-, IgM-, and IgG-class rheumatoid factors (RF), and of antibodies to cyclic cit
231 tended oligoarthritis, polyarthritis (either rheumatoid factor [RF] positive or RF negative), or syst
232 stemic inflammation and RA disease severity (rheumatoid factor [RF] seropositivity, erythrocyte sedim
233 B cells with specificity for self-IgG2a (the rheumatoid factor [RF] specificity) to understand how no
234 isit for any of 5 RA-related autoantibodies (rheumatoid factor [RF], anti-cyclic citrullinated peptid
235 , 42 with persistent oligoarthritis, 45 with rheumatoid factor [RF]-negative polyarthritis, and 21 wi
236                                              Rheumatoid factors (RFs) are a dominant class of autoant
237  mapped the specificity of 28 monoclonal IgM rheumatoid factors (RFs) produced by heterohybridomas de
238  and serum levels of BLyS, IgM, IgA, and IgG rheumatoid factors (RFs), anti-cyclic citrullinated pept
239                                              Rheumatoid factors (RFs)-IgM and -IgA were measured by E
240 resence of erosions at baseline, presence of rheumatoid factor, rheumatoid factor titer, and HLA-DRB1
241               In contrast to the functional, rheumatoid factor-secreting CD27(+)CD21(high) subset, th
242  and does not efficiently differentiate into rheumatoid factor-secreting plasmablasts, suggesting tha
243                         Within the RA group, rheumatoid factor seropositivity and higher cumulative p
244 isability scores, C-reactive protein levels, rheumatoid factor seropositivity, and a lack of current
245 deformed joint counts, subcutaneous nodules, rheumatoid factor seropositivity, and erythrocyte sedime
246 ed CIA predominantly in females and produced rheumatoid factors, similar to the features of human RA.
247 AB29 transgenic mice expressing a hIgM/kappa rheumatoid factor specific for human IgG, with no detect
248 n between the presence of erosive disease or rheumatoid factor status and the dose of rheumatoid epit
249 odified Larsen score, demographic variables, rheumatoid factor status, and carriage of HLA-DRB1 share
250  age but were largely similar across sex and rheumatoid factor status, as were the HRs for VTE across
251  for age, sex, body mass index, smoking, and rheumatoid factor status.
252 as were the HRs for VTE across age, sex, and rheumatoid factor status.
253 ic and nephritogenic activities of 6-19 IgG3 rheumatoid factor, terminal sialylation attenuated the n
254 ormal level, <10 mg/L), were normal, and the rheumatoid factor test result was negative.
255 toantibodies to histones, DNA, or IgG (i.e., rheumatoid factors), the Vkappa regions, with those from
256 edimentation rate [ESR], C-reactive protein, rheumatoid factor, the HLA-DRB1 shared epitope, and cumu
257 pondyloarthropathies are not associated with rheumatoid factor, they show a strong association with H
258  at baseline, presence of rheumatoid factor, rheumatoid factor titer, and HLA-DRB1*04 alleles, partic
259                                              Rheumatoid factor titer, HLA-DRB1 polymorphisms, age, an
260 unt of fibrosis and the percentage of CP and rheumatoid factor titer, yet neither of the latter param
261  antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients.
262 -small nuclear ribonucleoprotein (snRNP) and rheumatoid factor titers, but failed to promote the deve
263  lysozyme BCR transgenic strain and the AM14 rheumatoid factor transgenic strain.
264 elapse was associated with high pretreatment rheumatoid factor values, and FCR was inversely associat
265 d two distinct more galactosylated 6-19 IgG3 rheumatoid factor variants.
266 or associations between RA and RF+ (positive rheumatoid factor) vs. mental health (depression, anxiet
267                                              Rheumatoid factor was not detected.
268 s, antidrug antibodies, body mass index, and rheumatoid factor were independently inversely associate
269 f rheumatoid arthritis positive for ACPA and rheumatoid factor with inflammatory joint pain were recr

 
Page Top